These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10943744)

  • 21. [Graves' disease and papillary thyroid cancer--coincidence or association?].
    Kinkel B; Bucerius J; Risse JH
    Dtsch Med Wochenschr; 2007 May; 132(18):983-6. PubMed ID: 17457781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative changes in thyrotropin-binding inhibitory immunoglobulin level in patients with Graves' disease: is subtotal thyroidectomy a suitable therapeutic option for patients of childbearing age with Graves' disease?
    Sugino K; Ito K; Ozaki O; Mimura T; Iwasaki H; Wada N
    World J Surg; 1999 Jul; 23(7):727-31. PubMed ID: 10390595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy.
    Ueta Y; Fukui H; Murakami H; Yamanouchi Y; Yamamoto R; Murao A; Santou Y; Taniguchi S; Mitani Y; Shigemasa C
    Thyroid; 1999 Feb; 9(2):179-82. PubMed ID: 10090319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graves' disease in a mediastinal mass presenting after total thyroidectomy for nontoxic multinodular goiter: a case report.
    Cunha FM; Rodrigues E; Oliveira J; Saavedra A; Vinhas LS; Carvalho D
    J Med Case Rep; 2016 Mar; 10():70. PubMed ID: 27029843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Graves' disease.
    Basaria S; Salvatori R
    J Endocrinol Invest; 2002; 25(7):639-42. PubMed ID: 12150341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
    Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
    Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
    Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol.
    Nachum Z; Rakover Y; Weiner E; Shalev E
    Am J Obstet Gynecol; 2003 Jul; 189(1):159-65. PubMed ID: 12861156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin.
    Yamaguchi Y; Inukai T; Iwashita A; Nishino M; Yamaguchi T; Shohda Y; Shimomura Y; Ohshima K; Kobayashi S; Kobayashi I
    Acta Endocrinol (Copenh); 1990 Oct; 123(4):411-5. PubMed ID: 1978459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of Graves' disease and papillary thyroid carcinoma with predominant production of thyroid-stimulation-blocking antibodies (TSBAb) persisted after total thyroidectomy.
    Nakamura S; Ishiyama-Takuno M; Kosaka J; Kondo K; Horiya Y; Hara S; Shima H; Shiraki T
    Endocrinol Jpn; 1992 Feb; 39(1):133-9. PubMed ID: 1351465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of TSH receptor antibody-positive hyperthyroidism with functioning metastases of thyroid carcinoma.
    Ishihara T; Ikekubo K; Shimodahira M; Iwakura T; Kobayashi M; Hino M; Oobayashi M; Kohno K; Kimura K; Kawamura S; Kurahachi H
    Endocr J; 2002 Apr; 49(2):241-5. PubMed ID: 12081245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
    Martino E; Balzano S; Bartalena L; Loviselli A; Sica V; Petrini L; Grasso L; Piga M; Braverman LE
    J Endocrinol Invest; 1991 Nov; 14(10):847-51. PubMed ID: 1687043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Papillary thyroid microcarcinoma in a boy with Graves' disease: a case report and review of the literature.
    Tuli G; Munarin J; Tessaris D; Quaglino F; de Sanctis L
    Pediatr Endocrinol Diabetes Metab; 2022; 28(1):88-90. PubMed ID: 34928110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship among thyrotropin (TSH), thyroid stimulating immunoglobulins, and results of triiodothyronine (T3) suppression test in patients with Graves' disease.
    Horimoto M; Nishikawa M; Uno C; Yoshikawa N; Taniguchi N; Inada M
    Endocrinol Jpn; 1988 Dec; 35(6):841-8. PubMed ID: 2471633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.